Table 3. ECG interval changes over time, by treatment.

	HAT Stage 1			HAT Stage 2
	DB289	pentamidine	p-value	melarsoprol	eflornithine	p-value
	(N = 229)	(N = 177)		(N = 47)	(N = 9)
PQ msec, mean (SD)
Baseline	161 (26)	157 (20)	0.091	169 (26)	170 (20)	0.914
During treatment	163 (24)	155 (26)*	0.056	nd	nd	na
At end of treatment	166 (25)	161 (21)	0.037	168 (26)	158 (14)	0.269
p-value	0.810	0.683		0.557	0.714
QRS msec, mean (SD)
Baseline	79 (8)	80 (9)	0.237	82 (8)	79 (11)	0.337
During treatment	79 (8)	82 (9)*	0.033	nd	nd	na
At end of treatment	79 (8)	81 (13)	0.057	79 (6)	77 (5)	0.353
p-value	0.699	0.939		0.483	0.155
QTc msec, mean (SD)
Baseline	422 (26)	419 (30)	0.282	420 (23)	441 (29)	0.020
During treatment	419 (27)	413 (22)*	0.185	nd	nd	na
At end of treatment	419 (24)	417 (24)	0.406	427 (27)	408 (23)	0.053
p-value	0.355	0.417		0.183	0.021

*: ECG during treatment was only performed in n = 40 patients in the pentamidine group

nd: ECGs not done

na: not applicable